Items tagged with Access
As global markets for generic drugs fail, poor people pay the price (post)
Healthy competition from generic drugs is often held up as a “cure” for high drug prices — a shared concern across rich and developing countries alike. For many low- and middle-income countries, however, a new report from the Center for Global Development that we co-authored shows that global markets for generic medicines are failing, leaving the poorest patients without safe and affordable essential medicines.
New milestone for children with TB reached as one million treatments of child-friendly medicines are ordered (post)
SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered by 93 countries in the three years since introduction of the products.1 The new medicines, which were first introduced nationally in Kenya in September 2016, are easier for caregivers to administer and for children to take. The announcement took place at the first International Global Health Security Conference in Sydney.
Roche expands the Global Access Program beyond HIV to also include diagnostic tests for TB, hepatitis and HPV (post)
-- Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals
-- Improving access to reliable diagnostics for disease management in countries with the highest burden
-- Early detection of infectious diseases with diagnostics helps clinicians save lives
High price delays introduction of new TB prevention therapy (post)
Despite being an ancient disease, tuberculosis (TB) remains the world’s leading infectious disease killer from a single infectious agent. For decades effective preventive therapy has existed, but has not been widely used. Recent optimism about a shorter and safer form of prevention therapy has been dampened because of its high price. While price negotiations continue behind closed doors, Spotlight asks when this new therapy will become available in South Africa.
India’s reliance on bedaquiline donations limits access to the key anti-TB drug (post)
On 24 March 2016, on the occasion of World Tuberculosis Day, JP Nadda, India’s health minister at the time, announced the launch of bedaquiline in India. Bedaquiline is a new anti-tuberculosis drug that works on patients with drug-resistant TB, or DR-TB. The government announced that it would be giving the drug for free, under a national programme to eliminate TB.
India must test new TB drug: Survivors appeal to Minister Harsh Vardhan (post)
Tuberculosis activists have appealed to Union Health Minister Dr Harsh Vardhan requesting India to test a new TB drug, which has been approved by the USFDA.
A simple regimen can prevent TB. Why aren’t more people on it? (post)
Two antibiotics, taken for a month, can stop a leading killer. But “when it’s for TB, people just sort of shrug.”
Mylan working on launch of new TB drug in India (post)
Multinational pharmaceutical company Mylan is working with Drug Controller General of India (DCGI) to launch pretomanid, a medicine used to treat drug-resistant TB, said a company top-official.
TB Alliance and Macleods announce commercial partnership for new therapy for highly drug-resistant TB (post)
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories.
Analysis: South Africa secures good prices for TB medicines, with one exception (post)
An article published in Spotlight compares prices in recent South African Government tender for TB medicines versus global prices available via the Global Drug Facility. The article covers bedaquiline, delamanid, linezolid and rifapentine.
Page 39 of 83 · Total posts: 0
←First 38 39 40 Last→